Semax Dosage Chart: 0.1% vs 1% Concentration, mcg Per Spray, and Cycling Protocol

Semax disappears from your bloodstream in roughly 2 minutes. A 1996 double-blind, placebo-controlled trial in healthy volunteers measured cognitive effects lasting 20 to 24 hours from a single dose. Both numbers are accurate. The reason they coexist is the most important thing to understand before calculating your first dose, and it explains why dosing instructions that say "three times daily" are almost always wrong.

This guide covers the full Semax dosage chart by concentration, the calculation error behind most failed protocols, and what the Russian clinical data actually shows versus what works for cognitive enhancement.

Semax is a seven-amino-acid synthetic analog of ACTH 4-10, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the early 1980s. Russia approved it for clinical use in ischemic stroke, cognitive disorders, and optic nerve disease, and has maintained it on its List of Vital and Essential Drugs since 2011. The US FDA scheduled a formal compounding review for July 2026 that could change its legal status for licensed US pharmacies.

The mechanism relevant to cognitive use is BDNF upregulation via CREB activation. A single dose turns on BDNF and NGF gene expression in hippocampal neurons within hours. A 2018 study by Gusev et al. in Zh Nevrol Psikhiatr confirmed measurable plasma BDNF increases in 110 post-stroke patients on a 6,000 mcg daily protocol. Semax also facilitates dopamine release in the striatum within the first 1 to 4 hours, which is why the cognitive and motivational effects tend to register faster than the neuroplasticity benefits.

Semax Dosage Chart: 0.1% vs 1% Side by Side

The most important framing before this table: the dose for cognitive enhancement in healthy adults and the dose for acute ischemic stroke treatment are separated by a factor of 20 to 30. They come from completely different research contexts with completely different risk profiles. Know which category you are working in before you calculate anything.

Use case	Solution	Per spray	Daily dose range	Typical cycle
Cognitive enhancement, beginner	0.1% (1 mg/mL)	100 mcg	100-200 mcg	5-7 days
Cognitive enhancement, standard	0.1% (1 mg/mL)	100 mcg	200-600 mcg	10-14 days
Cognitive enhancement, upper range	0.1% (1 mg/mL)	100 mcg	600-1,000 mcg	10-14 days
Acute ischemic stroke (Russian clinical)	1% (10 mg/mL)	1,000 mcg	12,000-18,000 mcg	5-10 days (inpatient)
Post-stroke rehabilitation	1% (supervised)	1,000 mcg	6,000 mcg	2 x 10-day courses

Using the 0.1% solution for cognitive enhancement

The 0.1% solution delivers 1 mg of Semax per mL. A standard nasal spray pump actuates 0.1 mL per spray, giving you 100 mcg per actuation. Russian commercial dropper bottles (Peptogen brand) deliver approximately 50 mcg per drop. Three drops per nostril from a Russian dropper equals roughly 300 mcg per session.

The Kaplan 1996 trial used 0.25 to 1.0 mg in healthy adults, which maps to 2 to 10 sprays of a 0.1% pump formulation per day. Most people find 200 to 400 mcg (2 to 4 sprays) as the practical sweet spot, with effects peaking within 30 to 60 minutes and lasting most of the day from a single morning dose.

Using the 1% solution: clinical only

The 1% solution delivers 10 mg per mL, giving 1,000 mcg per standard spray. This is the concentration used in Russian stroke trials at 12 to 18 mg per day total. These are supervised inpatient protocols for acute neurological injury. If you ordered the 1% solution thinking it would be "stronger" for focus or memory, the next section explains why that reasoning breaks down badly in practice.

Why Confusing 0.1% and 1% Is a 10x Dosing Error

The two products look nearly identical in a bottle. Labels are sometimes ambiguous. Many protocols in circulation do not specify which concentration they were written for. The math consequence of confusing them is severe, and it runs in both directions.

Here is the pattern behind most "Semax does nothing" complaints: a user buys the 0.1% bottle, reads a community protocol that was actually written for 1%, and takes one-tenth of what they expected. No effect. They conclude the peptide is overhyped. Flip the error: a user gets the 1% bottle, follows "2-3 drops per nostril" instructions from a 0.1% source, and takes 10x the intended dose. Anxiety, racing heart, and disrupted sleep follow. They conclude Semax is poorly tolerated.

Check the label. Calculate the mcg per spray based on your actual concentration. Every time, before every batch.

What 30 Years of Russian Trials Actually Dosed

A single intranasal dose of 0.25 to 1.0 mg Semax improved memory test accuracy to 71 percent in healthy male volunteers versus 41 percent in the placebo group. Cognitive and electrophysiological effects were measured for 20 to 24 hours post-administration in a double-blind, placebo-controlled crossover design.

Kaplan et al., Neuroscience Research Communications, 1996

This is the foundational human trial. It established three things that matter for nootropic use. First, Semax produces measurable cognitive effects in healthy adults at doses that translate to 2 to 10 sprays of a 0.1% formulation per day. Second, the effect duration outlasts the plasma half-life by a factor of roughly 720, consistent with direct olfactory-to-CNS delivery that bypasses the blood-brain barrier. Third, tolerability across all tested doses was clean: no serious adverse events, with only mild nasal irritation in some subjects.

The stroke literature pushed doses into a completely different range. Gusev et al. 1997 ran the registration trial for Russia's stroke indication: 30 acute stroke patients received 12 mg per day for moderate strokes and 18 mg per day for severe strokes, using the 1% solution within 24 hours of onset for 5 to 10 days. Neurological deficit scores improved significantly at days 14 and 28. A 2018 meta-analysis by Shmonin et al. in Bulletin of Rehabilitation Medicine reviewed 8 Russian RCTs across 654 screened and 181 included patients, and found consistent NIHSS score reduction at days 10 to 14 with the 12 to 18 mg daily protocol, alongside improved Rivermead Mobility Index scores across subgroups.

Both bodies of research are real. They are not describing the same use case, or even the same order of magnitude of dosing. The cognitive enhancement trial used 0.25 to 1 mg. The stroke trials used 12 to 18 mg under hospital supervision. The gap between them is not a dosing ladder you should climb independently.

How Long Should You Actually Cycle Semax?

Russian clinical protocols ran Semax in structured courses: 5 to 14 days on, followed by a rest period. The post-stroke rehabilitation data from Gusev et al. 2018 (110 patients, PMID 29798983) used two 10-day courses separated by a 20-day interval. That structure has carried into community nootropic practice as the default cycling approach.

There is no published receptor desensitization data specific to Semax. It does not bind to a single high-affinity receptor that downregulates under daily stimulation the way GH secretagogue receptors do. The working hypothesis for cycling is that the BDNF upregulation response normalizes with sustained CREB activation, so effect magnitude diminishes around week 2 even without strict receptor downregulation. The dial that Semax turned up gradually returns to baseline under continuous stimulation.

Protocol type	On period	Off period	Basis
First use	5-7 days	5-7 days minimum	Community consensus
Standard cognitive protocol	10-14 days	10-14 days	Adapted from Russian clinical template
Russian stroke rehabilitation	2 x 10-day courses	20 days between courses	Gusev et al. 2018

The most common cycling mistake is continuous use past 14 days without a break. Users who report "the Semax effect faded at 2 weeks" are describing this normalization, not product failure or tolerance in the pharmacological sense. A 2-week break typically restores the initial response level. If you want to understand whether the stimulating or calming direction is what your situation actually calls for, the Semax vs Selank comparison covers that decision in detail.

Your BDNF and Dopamine Genes Change How Semax Hits

Semax operates through two primary pathways: BDNF upregulation and dopamine facilitation. The genetic variants that set your baseline in each pathway predict how much room Semax has to move the needle.

For BDNF, Val66Met is the key predictor. Met-allele carriers have impaired activity-dependent BDNF secretion, releasing roughly 30 percent less BDNF during learning and stress than Val/Val carriers. That lower baseline creates more room for Semax's BDNF-boosting effect to register. Met carriers often report sharper effects from lower doses precisely because they are the group with the most deficit to close. The brain-fog peptide guide covers this BDNF variant in more detail, with broader nootropic context for people who want to compare options.

For dopamine, COMT is the primary predictor. Fast-COMT (Val/Val) carriers clear prefrontal dopamine quickly, running lower on PFC dopamine at baseline. They tend to get the sharpest focus and motivation response from Semax because the dopaminergic facilitation fills a real deficit. Slow-COMT (Met/Met) carriers already have elevated PFC dopamine. Adding Semax can occasionally tip them into over-arousal, especially at doses above 400 mcg. If this describes you, start at 100 mcg and only move up after confirming your sleep is undisturbed for 3 to 4 days.

DRD2 receptor variants are a secondary consideration. Low-activity DRD2 genotypes reduce dopamine signaling in reward and motivation circuits. The motivational and drive effects of Semax tend to land harder for these carriers. For a deeper look at how BDNF receptor signaling genetics plays out across nootropic peptides, the Dihexa guide covers the same genetic landscape from the angle of TrkB activation. Both peptides converge on overlapping genetic predictors.

One thing Semax is unusual for: its clearance is handled by plasma enkephalinase and carboxypeptidase N, not by CYP liver enzymes. Your CYP3A4 or CYP2D6 metabolizer status has no meaningful effect on how Semax is processed or how long its effects last. This is one of the few nootropic peptides where CYP genetics are essentially irrelevant. Check your Semax peptide profile to see how your full genetic panel maps to this peptide specifically.